Fluvoxamine response

Selective serotonin reuptake inhibitors (SSRIs) are used for the treatment of major depressive and anxiety disorders, and may be used to treat other psychiatric conditions. Fluvoxamine is metabolized by cytochrome P450 2D6 (CYP2D6) and variations in CYP2D6 may affect drug exposure. CYP2D6 poor metabolizers showed greater drug exposure to fluvoxamine compared to extensive metabolizers at similar drug doses while data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy. Therapeutic guidelines for the SSRI fluvoxamine based on CYP2D6 genotype have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and are available on the PharmGKB website.

PharmGKB